Direct Comparison of Antigen Production and Induction of Apoptosis by Canarypox Virus- and Modified Vaccinia Virus Ankara-Human Immunodeficiency Virus Vaccine Vectors
- 1 July 2007
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 81 (13) , 7022-7033
- https://doi.org/10.1128/jvi.02654-06
Abstract
Recombinant poxvirus vectors are undergoing intensive evaluation as vaccine candidates for a variety of infectious pathogens. Avipoxviruses, such as canarypox virus, are replication deficient in mammalian cells by virtue of a poorly understood species-specific restriction. Highly attenuated vaccinia virus strains such as modified vaccinia virus Ankara (MVA) are similarly unable to complete replication in most mammalian cells but have an abortive-late phenotype, in that the block to replication occurs post-virus-specific DNA replication. In this study, an identical expression cassette for human immunodeficiency virus gag, pro, and env coding sequences was placed in canarypox virus and MVA vector backbones in order to directly compare vector-borne expression and to analyze differences in vector-host cell interactions. Antigen production by recombinant MVA was shown to be greater than that from recombinant canarypox virus in the mammalian cell lines and in the primary human cells tested. This observation was primarily due to a longer duration of antigen production in recombinant MVA-infected cells. Apoptosis induction was found to be more profound with the empty canarypox virus vector than with MVA. Remarkably, however, the inclusion of a gag/pro/env expression cassette altered the kinetics of apoptosis induction in recombinant MVA-infected cells to levels equal to those found in canarypox virus-infected cells. Antigen production by MVA was noted to be greater in human dendritic cells and resulted in enhanced T-cell stimulation in an in vitro antigen presentation assay. These results reveal differences in poxvirus vector-host cell interactions that should be relevant to their use as immunization vehicles.Keywords
This publication has 55 references indexed in Scilit:
- Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120JAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Differences and Similarities in Viral Life Cycle Progression and Host Cell Physiology after Infection of Human Dendritic Cells with Modified Vaccinia Virus Ankara and Vaccinia VirusJournal of Virology, 2006
- Cellular and Biochemical Differences between Two Attenuated Poxvirus Vaccine Candidates (MVA and NYVAC) and Role of the C7L GeneJournal of Virology, 2006
- Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteersVaccine, 2006
- High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human SubjectsThe Journal of Infectious Diseases, 2005
- Induction of Neutralizing Antibodies and Gag-Specific Cellular Immune Responses to an R5 Primary Isolate of Human Immunodeficiency Virus Type 1 in Rhesus MacaquesJournal of Virology, 2001
- Canarypox Virus-Induced Maturation of Dendritic Cells Is Mediated by Apoptotic Cell Death and Tumor Necrosis Factor Alpha SecretionJournal of Virology, 2000
- Apoptosis Induction by Human Immunodeficiency Virus Type 1 (HIV-1) gp120 PeptidesViral Immunology, 1997
- Poxvirus-Based Vectors as Vaccine CandidatesBiologicals, 1995
- HIV-1 gp120-dependent induction of apoptosis in antigen-specific human T cell clones is characterized by ‘tissue’ transglutaminase expression and prevented by cyclosporin AFEBS Letters, 1994